NCT04120311View on ClinicalTrials.gov

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Macular EdemaRadiation RetinopathyBranch Retinal Vein OcclusionEpiretinal MembraneCentral Serous Retinopathy With Pit of Optic DiscCommotio RetinaeVitritis

Interventions

DRUG

Episcleral Dexamethasone

Sustained Release Episcleral Dexamethasone

Trial Locations (1)

94303

Stanford Medicine Ophthalmology, Palo Alto

All Listed Sponsors

lead

Targeted Therapy Technologies, LLC

INDUSTRY